EyeGate Promotes Sarah Romano to Chief Financial Officer
January 04 2018 - 8:30AM
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the
“Company”), a clinical-stage, specialty pharmaceutical company with
two platform technologies for treating diseases and disorders of
the eye, today announced the promotion of Sarah Romano from Interim
Chief Financial Officer to Chief Financial Officer, effective
January 1, 2018.
“I am pleased to announce Sarah’s promotion to
Chief Financial Officer. Since joining EyeGate nearly two years
ago, Sarah has been actively involved in the development of our
financial systems and processes, and she has been responsible for
all corporate finance and accounting activities of the Company
since becoming Interim Chief Financial Officer last year. Sound
financial planning and implementation are increasingly important as
our pipeline advances through the clinic and into
commercialization. With her deep understanding of our business,
Sarah is well suited to lead our finance team,” commented Stephen
From, President and Chief Executive Officer of EyeGate.
Ms. Romano joined EyeGate in 2016 serving as Corporate
Controller. She was promoted to Interim Chief Financial Officer on
February 1, 2017.
Prior to joining EyeGate, Ms. Romano served as Assistant
Controller at TechTarget and Corporate Controller at Bowdoin Group,
a healthcare-focused executive recruiting firm. Previously, she
held financial reporting positions of increasing responsibility at
SoundBite Communications until its acquisition by Genesys in 2013,
and was a Senior Financial Reporting Analyst at Cognex Corporation,
a publicly-traded manufacturer of machine vision systems, software
and sensors. Ms. Romano began her career as an Auditor in the
Boston office of PricewaterhouseCoopers. A licensed CPA in
Massachusetts, she holds a Bachelor of Arts in Accounting from
College of the Holy Cross and Masters of Accounting from Boston
College.
“I am truly excited and grateful to be promoted to this
position, especially at such a critical time in EyeGate’s corporate
development. I look forward to continue working with Stephen and
our talented team as we focus on executing our growth strategy and
driving value for our shareholders,” added Sarah Romano, Chief
Financial Officer of EyeGate.
About EyeGateEyeGate is a clinical-stage
specialty pharmaceutical company focused on developing and
commercializing products using its two proprietary platform
technologies for treating diseases and disorders of the eye.
EyeGate’s CMHA-S platform is based on cross-linking thiolated
carboxymethyl hyaluronic acid, a modified form of the natural
polymer hyaluronic acid (“HA”). This is a gel that possesses unique
physical and chemical properties such as hydrating and healing when
applied to the ocular surface. The ability of CMHA-S to adhere
longer to the ocular surface, resist degradation and protect the
ocular surface makes it well-suited for treating various ocular
surface injuries.
EGP-437, EyeGate’s other product in clinical trials,
incorporates a reformulated topically active corticosteroid,
Dexamethasone Phosphate, that is delivered into the ocular tissues
through EyeGate’s proprietary innovative drug delivery system, the
EyeGate II Delivery System. www.EyeGatePharma.com.
EyeGate Social Media
EyeGate uses its website (www.EyeGatePharma.com), Facebook page,
corporate Twitter account, and LinkedIn page as channels of
distribution of information about EyeGate and its product
candidates. Such information may be deemed material information,
and EyeGate may use these channels to comply with its disclosure
obligations under Regulation FD. Therefore, investors should
monitor EyeGate’s website and its social media accounts in addition
to following its press releases, SEC filings, public conference
calls, and webcasts. The social media channels that EyeGate
intends to use as a means of disclosing the information described
above may be updated from time to time as listed on EyeGate’s
investor relations website.
Forward-looking Statements
Some of the statements in this press release are
“forward-looking” and are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These “forward-looking” statements include statements relating to,
among other things, the commercialization efforts and other
regulatory or marketing approval efforts pertaining to EyeGate’s
products, including EyeGate’s EGP-437 combination product and those
of Jade Therapeutics, Inc., a wholly owned subsidiary of EyeGate,
as well as the success thereof, with such approvals or success may
not be obtained or achieved on a timely basis or at all. These
statements involve risks and uncertainties that may cause results
to differ materially from the statements set forth in this press
release, including, among other things, certain risk factors
described under the heading “Risk Factors” contained in our Annual
Report on Form 10-K filed with the SEC on February 23, 2017 or
described in EyeGate’s other public filings. EyeGate’s results may
also be affected by factors of which EyeGate is not currently
aware. The forward-looking statements in this press release speak
only as of the date of this press release. EyeGate expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to such statements to reflect any change in
its expectations with regard thereto or any changes in the events,
conditions or circumstances on which any such statement is
based.
Contact:Lee Roth / Janhavi MohiteThe Ruth Group for EyeGate
Pharmaceuticals646-536-7012 / 7026lroth@theruthgroup.com /
jmohite@theruthgroup.com
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AB Corporate Bond ETF (NASDAQ:EYEG)
Historical Stock Chart
From Apr 2023 to Apr 2024